Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H18N2O.C7H6O2 |
| Molecular Weight | 340.4162 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1.COC2=CC=C3NC=C(CCN(C)C)C3=C2
InChI
InChIKey=ZDRGFCJVIIDWMH-UHFFFAOYSA-N
InChI=1S/C13H18N2O.C7H6O2/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13;8-7(9)6-4-2-1-3-5-6/h4-5,8-9,14H,6-7H2,1-3H3;1-5H,(H,8,9)
N,N-Dimethyl-5-Methoxytryptamine (aka 5-MeO-DMT) is a psychedelic of the tryptamine class. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. Like its close relatives DMT and bufotenin (5-HO-DMT), it has been used as an entheogen in South America. It can also be found in the dart poison traditionally used by the Yanoama Indians of Upper Orinoco. It acts as a non-selective serotonin (5-HT) agonist. -MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine. 5-MeO-DMT is classified as a controlled substance in China, Australia, Sweden, Turkey, and the USA.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Methylated and unmethylated indolamine in the cisternal fluid in acute endogenous psychoses]. | 1983 |
|
| Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. | 1993 Aug 25 |
|
| Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. | 1993 Jan 15 |
|
| Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. | 1998 Nov |
|
| High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. | 1999 May |
|
| Effects of serotoninergic drugs on tremor induced by physostigmine in rats. | 2000 May |
|
| Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS. | 2001 |
|
| Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method. | 2001 Feb 10 |
|
| [(3)H]-serotonin release from bovine iris-ciliary body: pharmacology of prejunctional serotonin (5-HT(7)) autoreceptors. | 2001 Jul |
|
| Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. | 2001 Oct-Dec |
|
| The role of 5-HT(1A) receptors in control of lower urinary tract function in cats. | 2002 Aug 16 |
|
| Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinol-induced impairment of spatial memory. | 2002 Jun 12 |
|
| 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. | 2002 May |
|
| Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. | 2003 Jul |
|
| Identification of cytokinins produced by the plant parasitic nematodes Heterodera schachtii and Meloidogyne incognita. | 2003 Jul 1 |
|
| Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. | 2003 Jun |
|
| Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. | 2003 Nov |
|
| The Meixner test in the detection of alpha-amanitin and false-positive reactions caused by psilocin and 5-substituted tryptamines. | 2004 Aug |
|
| Binding of tryptamine analogs at h5-HT1E receptors: a structure-affinity investigation. | 2004 May 15 |
|
| Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. | 2004 Sep |
|
| The rapid analysis of heroin drug seizures using micellar electrokinetic chromatography with short-end injection. | 2005 Jan |
|
| Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies. | 2005 Jul 11 |
|
| A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. | 2005 Nov-Dec |
|
| The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. | 2006 Dec |
|
| Efficient and sensitive method for quantitative analysis of alkaloids in hardinggrass (Phalaris aquatica L.). | 2006 Dec 13 |
|
| Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. | 2006 Dec 20 |
|
| Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. | 2006 Jan-Feb |
|
| A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. | 2006 Jul-Aug |
|
| The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. | 2007 Mar 22 |
|
| Neurobiology of spirituality. | 2008 Jan |
|
| Solubilization of 5-methoxy tryptamine molecular probes in CTAB and SDS micelles: a cmc and binding constant study. | 2008 Mar |
|
| Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. | 2008 Nov |
|
| Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule. | 2010 Dec 20 |
Sample Use Guides
10 mg of 5-MeO-DMT administrated intranasally or sublingually causes a significant visionary response.
Route of Administration:
Other
Membranes were prepared from the cerebral cortex and striatum of Male SD rats and maintained in HEPES buffer pH 7.6, 20 mM HEPES, 7 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 0.2 mM dithiothreitol (DTT). Cells were plated in 96 wells containing an assay buffer of 25 mM HEPES, pH 7.6, 7 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 0.2 mM DTT and 10 mM DPCPX. Each well also received various concentrations screening compounds, DA, 5-HT, NE, and the mixture of brain membranes (2 mg protein/well for the striatum and 4 mg protein/well for the cortex) and 150 micro-M GDP. This mixture was pre-incubated at 30 °C for 20 minutes with shaking. Incubation was started by adding 0.1 nM [35S]GTPgS to a total volume of 100 mL and continued at 30 °C for 90 minutes with shaking. The reaction was stopped by rapid filtration and retained membrane-bound radioactivity on the filter was measured by liquid scintillation counting. 5-MeODMT was found to have an EC50 of 3.8 x 10^07 M.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MF2UDH4QUF
Created by
admin on Sat Dec 16 19:56:36 GMT 2023 , Edited by admin on Sat Dec 16 19:56:36 GMT 2023
|
PRIMARY | |||
|
282103-25-7
Created by
admin on Sat Dec 16 19:56:36 GMT 2023 , Edited by admin on Sat Dec 16 19:56:36 GMT 2023
|
PRIMARY | |||
|
44783953
Created by
admin on Sat Dec 16 19:56:36 GMT 2023 , Edited by admin on Sat Dec 16 19:56:36 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
